Centene (NYSE:CNC) Stock Acquired Rep. Tim Moore

Key Points

• Representative Tim Moore of North Carolina disclosed the purchase of Centene Corporation (NYSE:CNC) stock worth between $1,001 and $15,000 on August 8th.
• Centene's most recent quarterly earnings report indicated a loss of ($0.16) EPS, significantly missing estimates while reporting a revenue of $48.74 billion, up 22.4% year-over-year.
• Centene is currently facing downgrades from multiple brokerages with revised price targets, including a drop from $68.00 to $28.00 by Robert W. Baird, reflecting a cautious outlook on the stock.

Representative Tim Moore (R-North Carolina) recently bought shares of Centene Corporation NYSE: CNC. In a filing disclosed on September 03rd, the Representative disclosed that they had bought between $1,001 and $15,000 in Centene stock on August 8th.

Representative Tim Moore also recently made the following trade(s):

• Sold $100,001 - $250,000 in shares of Centene NYSE: CNC on 8/18/2025.
• Sold $50,001 - $100,000 in shares of UnitedHealth Group NYSE: UNH on 8/15/2025.
• Sold $100,001 - $250,000 in shares of Intel NASDAQ: INTC on 8/13/2025.
• Sold $50,001 - $100,000 in shares of Hyster-Yale NYSE: HY on 8/13/2025.
• Purchased $15,001 - $50,000 in shares of Hyster-Yale NYSE: HY on 8/12/2025.
• Purchased $15,001 - $50,000 in shares of Intel NASDAQ: INTC on 8/11/2025.
• Purchased $15,001 - $50,000 in shares of UnitedHealth Group NYSE: UNH on 8/8/2025.
• Purchased $15,001 - $50,000 in shares of Intel NASDAQ: INTC on 8/8/2025.
• Purchased $15,001 - $50,000 in shares of Hyster-Yale NYSE: HY on 8/7/2025.
• Purchased $15,001 - $50,000 in shares of Centene NYSE: CNC on 8/7/2025.

Centene Price Performance

Shares of CNC opened at $28.62 on Friday. Centene Corporation has a 52-week low of $25.08 and a 52-week high of $77.29. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.10. The business's 50 day moving average price is $30.30 and its two-hundred day moving average price is $49.01. The firm has a market cap of $14.06 billion, a PE ratio of 7.08, a price-to-earnings-growth ratio of 1.22 and a beta of 0.44.

Centene (NYSE:CNC - Get Free Report) last issued its quarterly earnings results on Friday, July 25th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.39). Centene had a net margin of 1.15% and a return on equity of 9.57%. The business had revenue of $48.74 billion during the quarter, compared to analyst estimates of $44.71 billion. During the same period last year, the firm posted $2.42 earnings per share. Centene's quarterly revenue was up 22.4% compared to the same quarter last year. Centene has set its FY 2025 guidance at 1.750-1.750 EPS. On average, equities analysts anticipate that Centene Corporation will post 6.86 EPS for the current year.

Insider Buying and Selling at Centene

In other Centene news, Director Theodore R. Samuels II acquired 9,000 shares of the company's stock in a transaction dated Monday, July 28th. The stock was purchased at an average price of $27.62 per share, with a total value of $248,580.00. Following the completion of the purchase, the director directly owned 32,000 shares in the company, valued at approximately $883,840. The trade was a 39.13% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sarah London acquired 19,230 shares of the company's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $25.50 per share, with a total value of $490,365.00. Following the purchase, the chief executive officer owned 845,275 shares of the company's stock, valued at approximately $21,554,512.50. This trade represents a 2.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CNC. Robert W. Baird lowered their target price on Centene from $68.00 to $28.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Morgan Stanley decreased their price target on Centene from $33.00 to $28.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Wells Fargo & Company downgraded Centene from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $72.00 to $30.00 in a research note on Wednesday, July 23rd. UBS Group cut their price target on Centene from $45.00 to $31.00 and set a "neutral" rating for the company in a research note on Monday, July 28th. Finally, Wall Street Zen downgraded Centene from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Centene has a consensus rating of "Hold" and an average target price of $41.40.

Hedge Funds Weigh In On Centene

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB grew its position in Centene by 8.8% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,092 shares of the company's stock worth $127,000 after acquiring an additional 169 shares during the last quarter. Quadcap Wealth Management LLC raised its stake in Centene by 3.2% during the first quarter. Quadcap Wealth Management LLC now owns 5,617 shares of the company's stock valued at $341,000 after buying an additional 172 shares during the last quarter. Poinciana Advisors Group LLC raised its stake in Centene by 2.8% during the first quarter. Poinciana Advisors Group LLC now owns 7,221 shares of the company's stock valued at $438,000 after buying an additional 195 shares during the last quarter. Carnegie Investment Counsel raised its stake in Centene by 6.0% during the first quarter. Carnegie Investment Counsel now owns 3,811 shares of the company's stock valued at $234,000 after buying an additional 215 shares during the last quarter. Finally, Allworth Financial LP raised its stake in Centene by 6.1% during the first quarter. Allworth Financial LP now owns 4,387 shares of the company's stock valued at $270,000 after buying an additional 254 shares during the last quarter. 93.63% of the stock is currently owned by institutional investors.

About Representative Moore

Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina's 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Moore (Republican Party) ran for election to the U.S. House to represent North Carolina's 14th Congressional District. He won in the general election on November 5, 2024. Moore served as speaker of the House from 2015 to 2025. Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.